NCT01962532View on ClinicalTrials.gov

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Patients With Advanced or Refractory Solid Tumors or Lymphoma

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 21, 2013

Primary Completion Date

January 28, 2016

Study Completion Date

January 28, 2016

Conditions

NeoplasmsLymphomaAdenocarcinomaEsophagogastric Junction

Interventions

DRUG

Part 1: JNJ-42756493

JNJ-42756493 dose escalation starting at dose of 2 mg orally daily for 21-day cycles and 28 day cycles Intermitting dosing regimen (7 days on and 7 days off) up to the maximum tolerated dose in order to determine the recommended Phase 2 dose.

DRUG

Part 2: JNJ-42756493

Recommended Phase 2 JNJ-42756493 dose determined in Part 1 administered orally for 28-days cycles (Intermitting dosing regimen).

Trial Locations (3)

Unknown

Kashiwa

Matsuyama

Tokyo

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY

NCT01962532 - A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Patients With Advanced or Refractory Solid Tumors or Lymphoma | Biotech Hunter | Biotech Hunter